Don't want ads? Subscribe or login now.

Catalent Brass Face Investor Suit Over COVID Vaccine Woes

By Sydney Price · August 15, 2023, 1:44 PM EDT

The top brass of pharmaceutical company Catalent Inc. face a shareholder derivative suit in Delaware federal court over claims they lied to investors about the health of the company's finances and...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Husty v. Catalent, Inc. et al

Case Number

1:23-cv-00891

Court

Delaware

Nature of Suit

Stockholders Suits

Date Filed

August 11, 2023

Recent Articles By Sydney

May 01, 2024
Globe Life Hid Toxic Culture And Policy Fraud, Investors Say
April 30, 2024
SEC Fines Adviser Firm For Splitting Legal Fees With Client
January 24, 2024
BofA Fell For $2.1M Check Fraud Despite Red Flags, Suit Says
December 14, 2023
Arrow Financial Execs Accused Of Hiding Weak Controls
October 12, 2023
Borrowers Get Class Cert. In Mortgage Lender Kickback Suit
October 03, 2023
Car Insurtech Co., Underwriter To Pay $2.3M For Violations
September 06, 2023
Trade Group Says SEC Overstepped In Annuities Sales Suit
September 01, 2023
Hearing Aid Investors Lose 2nd Bid At Suit Over DOJ Probe
August 22, 2023
Fed Fines Regions Bank $3M For Flood Insurance Practices
August 15, 2023
Allstate Investors Ink $90M Settlement In Underwriting Suit